CClinicalTrials.gg
RecruitingNCT06692205Updated Nov 18, 2024

Effects of Primary Open-angle Glaucoma on Visual-motor Coordination

An observational study in Primary Open-angle Glaucoma, sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-18.

Sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
200
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Commonly used visual function assessments in glaucoma diagnosis and treatment-such as visual acuity, visual field, and contrast sensitivity-do not directly capture the impact of the disease on patients' daily abilities. While questionnaires can evaluate this impact from the patient's perspective, they are subject to individual biases and inconsistent evaluation standards. Thus, objective methods are needed to assess patients' abilities in visually guided daily activities. Grasping objects and avoiding obstacles are fundamental visually guided tasks that require effective visuomotor coordination. By attaching lightweight reflective markers to participants' limbs and using a motion capture system to track their movements in three-dimensional space, various indicators of planning, execution, and control in tasks such as object grasping and obstacle avoidance can be quantified, allowing for an objective evaluation of visuomotor coordination. However, it remains unclear how visuomotor coordination is affected in glaucoma patients at different disease stages or whether visual field damage in specific areas has distinct impacts on visuomotor coordination. This study, therefore, aims to investigate changes in visuomotor coordination among patients with primary open-angle glaucoma across disease stages and to determine the effects of visual field defects in different locations on their visuomotor abilities.

Read the detailed description

Glaucoma is the leading cause of irreversible blindness worldwide, with an estimated 110 million glaucoma patients expected globally among individuals aged 40-80 by 2040. As a chronic and progressive eye disease, glaucoma can cause significant impairments in visual function. These impairments can severely limit daily activities like searching, walking, and reading, leading to a significant decline in patients' vision-related quality of life. Evaluating the visual abilities of glaucoma patients can not only gauge the extent of the disease's impact on their visual function but also indicate the effectiveness of clinical treatments and rehabilitation strategies. However, commonly used clinical tests, such as visual acuity and visual field, only partially reflect visual function and do not directly measure the disease's impact on daily activities. Questionnaires can be designed to assess the impact of the disease on daily activities, from the patient's perspective. However, as a subjective assessment method, questionnaires are susceptible to individual biases and evaluation standards. Therefore, more objective methods are needed to evaluate patients' performance and abilities in executing daily visually guided activities.

Grasping objects and avoiding obstacles are fundamental visually guided activities that require good visuomotor coordination. The visual system supplies essential information about the spatial position and intrinsic properties of objects, while the brain integrates this information to guide and control limb movements for specific tasks. By attaching lightweight reflective markers, such as spheres or patches, to participants' limbs and using a motion capture system to track these markers in three-dimensional space, various indicators of planning, execution, and control during tasks can be quantified. This approach enables an objective assessment of participants' visuomotor coordination abilities.

Previous studies have shown that glaucoma patients differ from age-matched healthy controls in reaching-grasping tasks, though findings on these differences have been inconsistent. Furthermore, researchers have reported that glaucoma patients also face challenges with mobility. However, it remains unclear how visuomotor coordination in glaucoma patients is affected across different disease stages during tasks like object grasping and obstacle avoidance, or whether the location of visual field damage has varied effects on their visuomotor coordination. In this study, we aim to compare the performance of patients with primary open-angle glaucoma and age-matched healthy controls in reaching-grasping and mobility tasks. Our goal is to investigate changes in visuomotor coordination across different stages of the disease and to clarify how visual field defects in various locations impact patients' visuomotor abilities.

02

Conditions studied

  • Primary Open-angle Glaucoma

Keywords

  • Visual-motor coordination
  • glaucoma
03

In context

Glaucoma

1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.

This study's planned enrollment of 200 is above the median of 103 across 454 observational studies indexed under Glaucoma.

Browse Glaucoma studies →

Lead sponsor

Zhongshan Ophthalmic Center, Sun Yat-sen University is the lead sponsor of 159 studies on the registry; 77 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

  1. Primary open-angle glaucoma: patients with primary open-angle glaucoma diagnosed by glaucoma professionals
  2. Healthy controls: subjects with no history of ocular disease, except for refractive errors and cataracts, and who have a presenting visual acuity of 20/40 or better in both eyes, as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart.

Eligibility criteria

Inclusion Criteria:

1.1 Inclusion criteria of primary open-angle glaucoma group:

  1. Age between 18 and 75 years;
  2. Diagnosed with primary open-angle glaucoma, with no anti-glaucoma surgery scheduled within ±1 month;
  3. Best corrected visual acuity in one eye ≥ 6/12;
  4. Stereoscopic vision ≥ 1000 seconds of arc;
  5. Able to clearly communicate and cooperate with the completion of relevant assessments and data collection.

1.2 Inclusion criteria of healthy controls:

  1. Age between 18 and 75 years;
  2. No history of eye disease other than refractive error and cataract;
  3. Best corrected visual acuity in both eyes ≥ 6/12;
  4. Stereoscopic vision ≥ 1000 seconds of arc;
  5. Able to clearly communicate and cooperate with the completion of relevant assessments and data collection.

Exclusion Criteria:

1.1 Exclusion criteria for primary open-angle glaucoma group:

  1. Individuals with cognitive dysfunction, psychological dysfunction, hearing impairment, or other conditions that prevent normal communication;
  2. Presence of physical motor dysfunction, hyperthyroidism or hypothyroidism, malignant tumors, heart disease, or other systemic diseases;
  3. Presence of other ocular conditions affecting visual function (except cataract and refractive error), such as age-related macular degeneration, diabetic retinopathy, optic neuropathy, retinal vascular disease, etc.;
  4. Pregnant or lactating women.

1.2 Exclusion criteria for healthy controls:

  1. Individuals with cognitive dysfunction, psychological dysfunction, hearing impairment, or other conditions that prevent normal communication;
  2. Presence of physical motor dysfunction, hyperthyroidism or hypothyroidism, malignant tumors, heart disease, or other systemic diseases;
  3. Presence of other ocular conditions affecting visual function (except cataract and refractive error), such as age-related macular degeneration, diabetic retinopathy, optic neuropathy, retinal vascular disease, etc.;
  4. Pregnant or lactating women.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Primary open-angle glaucoma

    Patients with primary open-angle glaucoma diagnosed by glaucoma professionals

  • Healthy controls

    Healthy controls were required to have a presenting Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity of 20/40 or better in both eyes.

06

What researchers measure

Primary outcomes

  1. Overall movement duration of the reaching-and-grasping task

    Lightweight reflective markers are attached to the participants' thumb, index finger, and wrist joints, and a motion capture system is used to track the movement of these markers in three-dimensional space. The overall movement duration during the reaching-and-grasping task is then quantified. This overall movement duration serves as an index of task execution efficiency.

    Time frame: 1 day (Only once)

  2. Overall movement duration of the mobility task

    Lightweight reflective markers are attached to the participants' thigh, calf, and ankle joints, and a motion capture system is used to track the movement of these markers in three-dimensional space. The overall movement duration during the mobility task is then quantified, serving as an index of task execution efficiency during orientation and obstacle avoidance.

    Time frame: 1 day (Only once)]

Secondary outcomes

  1. ETDRS visual acuity

    The information of Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity was obtained from the hospital electronic medical record system or outpatient medical record data.

    Time frame: 1 day (Only once)]

  2. Automatic perimetry report

    Automatic perimetry reports were obtained from the hospital electronic medical record system or outpatient medical record data. Mean defect (MD), mode standard deviation (PSD), corrected mode standard deviation (CPSD), short-term fluctuation (SF), glaucoma half field analysis (GHT), paracentric scotoma, nasal staircase, arch scotoma, tubular field and other characteristic visual field defects were recorded.

    Time frame: 1 day (Only once)

  3. Pelli-Robson contrast sensitivity

    Pelli-Robson contrast sensitivity test card was used.

    Time frame: 1 day (Only once)

  4. Stereoacuity

    Stereoacuity was measured using the Titmus stereopsis test.

    Time frame: 1 day (Only once)

  5. Glaucoma Visual Functioning Questionnaire-40 (GVFQ-40)

    Glaucoma Visual Functioning Questionnaire-40 (GVFQ-40) is a 40-item questionnaire developed to evaluate the visual ability of glaucoma patients in detail. It consists of 40 items and measures the impact of glaucoma on restriction of participation in daily activities in five domains of functioning. Each item has six answer options, that is, no difficulty (score = 1), mild difficulty (score = 2), moderate difficulty (score = 3), extremely difficult (score = 4), completely unable to complete (score = 5), and do not perform for nonvisual reasons (no score). The GVFQ-40 is administered by a trained interviewer to all enrolled participants.

    Time frame: 1 day (Only once)

  6. National Eye Institute-Visual Function Questionnaire-25 (NEI VFQ-25)

    The National Eye Institute-Visual Function Questionnaire-25 (NEI VFQ-25) is a valid and reliable vision-related quality of life (QOL) questionnaire designed for persons who have chronic eye diseases or low vision. It includes 25 items that comprise 11 subscales on different aspects of vision-related functioning and QOL and 1 item on general health. NEI VFQ-25 scores range from 0 to 100, with a higher score representing better functioning.

    Time frame: 1 day (Only once)

  7. Short form 36 health survey questionnaire (SF-36)

    The Short Form 36 Health Survey Questionnaire (SF-36) is an instrument designed to measure health perception in a general population. It consists of 36 items and typically takes about five minutes to complete. The questionnaire assesses health across eight multi-item dimensions, covering functional status, well-being, and overall health evaluation. In six of the eight dimensions, patients are asked to rate their responses on three- or six-point scales. For each dimension, item scores are coded, summed, and transformed onto a scale ranging from 0 (worst health) to 100 (best health).

    Time frame: 1 day (Only once)

07

Study locations

1 of 1 sites recruiting
  • Zhongshan Opthalmic Center, Sun Yat-sen University
    Guangzhou, Guangdong 510060, China
    Recruiting
08

References and documents

Publications

  • Azoulay-Sebban L, Zhao Z, Zenouda A, Lombardi M, Gutman E, Brasnu E, Hamard P, Sahel JA, Baudouin C, Labbe A. Correlations Between Subjective Evaluation of Quality of Life, Visual Field Loss, and Performance in Simulated Activities of Daily Living in Glaucoma Patients. J Glaucoma. 2020 Oct;29(10):970-974. doi: 10.1097/IJG.0000000000001597. PubMed 32649451 ↗
  • Corveleyn X, Lenoble Q, Rouland JF, Boucart M. What is the Nature of the Reach-and-Grasp Deficit in Glaucoma? J Glaucoma. 2020 Sep;29(9):799-806. doi: 10.1097/IJG.0000000000001555. PubMed 32858724 ↗
  • Turano KA, Rubin GS, Quigley HA. Mobility performance in glaucoma. Invest Ophthalmol Vis Sci. 1999 Nov;40(12):2803-9. PubMed 10549639 ↗
  • Kotecha A, O'Leary N, Melmoth D, Grant S, Crabb DP. The functional consequences of glaucoma for eye-hand coordination. Invest Ophthalmol Vis Sci. 2009 Jan;50(1):203-13. doi: 10.1167/iovs.08-2496. Epub 2008 Sep 20. PubMed 18806294 ↗
  • Sivaprasad S, Tschosik E, Kapre A, Varma R, Bressler NM, Kimel M, Dolan C, Silverman D. Reliability and Construct Validity of the NEI VFQ-25 in a Subset of Patients With Geographic Atrophy From the Phase 2 Mahalo Study. Am J Ophthalmol. 2018 Jun;190:1-8. doi: 10.1016/j.ajo.2018.03.006. Epub 2018 Mar 10. PubMed 29530781 ↗
  • Ramulu PY, van Landingham SW, Massof RW, Chan ES, Ferrucci L, Friedman DS. Fear of falling and visual field loss from glaucoma. Ophthalmology. 2012 Jul;119(7):1352-8. doi: 10.1016/j.ophtha.2012.01.037. Epub 2012 Apr 4. PubMed 22480738 ↗
  • Bambo MP, Ferrandez B, Guerri N, Fuertes I, Cameo B, Polo V, Larrosa JM, Garcia-Martin E. Evaluation of Contrast Sensitivity, Chromatic Vision, and Reading Ability in Patients with Primary Open Angle Glaucoma. J Ophthalmol. 2016;2016:7074016. doi: 10.1155/2016/7074016. Epub 2016 Oct 31. PubMed 27872754 ↗
  • Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014 Nov;121(11):2081-90. doi: 10.1016/j.ophtha.2014.05.013. Epub 2014 Jun 26. PubMed 24974815 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06692205
Lead sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Responsible party
Sponsor
First posted
Nov 18, 2024
Start date
Nov 21, 2024 (estimated)
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Nov 18, 2024

Study contacts

Yehong Zhuo
Contact
zhuoyh@mail.sysu.edu.cn
02066619349
Haishun Huang
Contact
huanghsh9@mail2.sysu.edu.cn
13229518626

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion